Effect of Beta-blockers on Coronary Flow and Resistance in Patients With ANOCA
Effect of Beta-blockers on Coronary Flow and Resistance in Patients With ANOCA: a Randomised, Placebo-controlled, Mechanistic Study
VZW Cardiovascular Research Center Aalst
46 participants
Jul 3, 2025
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to learn whether beta-blockers can improve coronary blood flow and reduce resistance in patients with angina and no obstructive coronary arteries (ANOCA). The main questions it aims to answer are: * Do beta-blockers improve coronary blood flow in patients with ANOCA? * Do beta-blockers reduce coronary microvascular resistance in these patients? Researchers will compare a beta-blocker to a placebo to see if the medication has measurable effects on coronary circulation. Participants will: * Receive a beta-blocker or a placebo * Undergo specialized heart tests (such as coronary flow and resistance measurements) before and after treatment.
Eligibility
Inclusion Criteria3
- Patients undergoing diagnostic coronary angiography for suspected angina pectoris who are found to have ANOCA i.e. an FFR >0.80 and no diameter stenosis >50%
- Normal, TIMI 3 flow at angiography
- Stable haemodynamics
Exclusion Criteria8
- Clinical signs or symptoms of congestive heart failure
- Severe valvular heart disease requiring either surgical or percutaneous intervention
- History of coronary artery bypass grafting
- Tortuous coronary anatomy in which wire manipulation could be complex
- Heart rate <60 beats per minute
- Systolic blood pressure <100 mmHg
- Unable to give consent
- LVEF<40%
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
IV 0.9% NaCl (5 ml)
Metoprolol Tartrate (5 ml of 1 mg/ml solution for injection)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06864234